Smriti Iyengar

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats
    Smriti Iyengar
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 311:576-84. 2004
  2. ncbi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
  3. ncbi request reprint Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005
  4. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
  5. doi request reprint Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies
    Daniel K Kajdasz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 29:2536-46. 2007
  6. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
  7. doi request reprint 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity
    Matthew J Fisher
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA
    Bioorg Med Chem Lett 22:2514-7. 2012
  8. ncbi request reprint The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Pharm Des 11:1475-93. 2005
  9. ncbi request reprint Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
  10. ncbi request reprint The role of uninjured nerve in spinal nerve ligated rats points to an improved animal model of neuropathic pain
    Doo H Lee
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Pain 7:473-9. 2003

Collaborators

Detail Information

Publications24

  1. ncbi request reprint Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats
    Smriti Iyengar
    Eli Lilly and Co, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 311:576-84. 2004
    ..These data suggest that inhibition of both 5-HT and NE uptake may account for attenuation of persistent pain mechanisms. Thus, duloxetine may have utility in treatment of human persistent and neuropathic pain states...
  2. ncbi request reprint Efficacy and safety of duloxetine in patients with chronic low back pain
    Vladimir Skljarevski
    Lilly Research Laboratories, Indianapolis, IN, USA
    Spine (Phila Pa 1976) 35:E578-85. 2010
    ..This was a randomized, double-blind, placebo-controlled clinical trial...
  3. ncbi request reprint Duloxetine vs. placebo in patients with painful diabetic neuropathy
    David J Goldstein
    PRN Consulting and Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46285, USA
    Pain 116:109-18. 2005
    ..Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain...
  4. doi request reprint Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial
    Amy S Chappell
    Lilly Research Laboratories, Indianapolis, IN, USA
    Pain 146:253-60. 2009
    ..Adverse-event rates did not differ significantly between treatment groups (49.5% for duloxetine 60-120 mg/day, and 40.8% for placebo)...
  5. doi request reprint Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies
    Daniel K Kajdasz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Clin Ther 29:2536-46. 2007
    ....
  6. ncbi request reprint An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain
    Joachim F Wernicke
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pain Med 8:503-13. 2007
    ..To assess the safety of duloxetine at a fixed-dose of 60 mg twice daily (BID) for up to 52 weeks, and compare duloxetine with routine care in the management of patients with diabetic peripheral neuropathic pain (DPNP)...
  7. doi request reprint 3-Phenyl-5-isothiazole carboxamides with potent mGluR1 antagonist activity
    Matthew J Fisher
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46258, USA
    Bioorg Med Chem Lett 22:2514-7. 2012
    ..Oral administration of isothiazole 14 gave robust activity in the formalin model of persistent pain which correlated with CNS receptor occupancy...
  8. ncbi request reprint The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression
    Frank P Bymaster
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Curr Pharm Des 11:1475-93. 2005
    ..More importantly, duloxetine appears to have better response rates and remission from depressive symptoms, perhaps due to its ability to treat a wider range of symptoms...
  9. ncbi request reprint Effects of duloxetine on painful physical symptoms associated with depression
    David J Goldstein
    Department of Psychitry adn the Department of Pharmacology adn toxicology, Indiana Unibersity School of Medicine, Indianapolis, USA
    Psychosomatics 45:17-28. 2004
    ..Compared with placebo, duloxetine was associated with significant reduction in pain severity. The authors concluded that duloxetine reduces the painful physical symptoms of depression...
  10. ncbi request reprint The role of uninjured nerve in spinal nerve ligated rats points to an improved animal model of neuropathic pain
    Doo H Lee
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Eur J Pain 7:473-9. 2003
    ..The addition of a chromic gut loop around the intact L4 spinal nerve can augment the development of mechanical allodynia following SNL of L5. We propose this latter as a useful and practical animal model of neuropathic pain...
  11. ncbi request reprint Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Toronto, Canada
    J Palliat Med 9:29-40. 2006
    ....
  12. ncbi request reprint A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain
    Joel Raskin
    Lilly Research Laboratories, Eli Lilly Canada, Toronto, Ontario, Canada
    Pain Med 6:346-56. 2005
    ..Assess efficacy and safety of duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, on the reduction of pain severity, in patients with diabetic peripheral neuropathic pain (DPNP)...
  13. ncbi request reprint Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain
    Esteban Dominguez
    Centro de Investigación Lilly, S A Avda De la Industria 30, 28108 Alcobendas, Madrid, Spain
    J Med Chem 48:4200-3. 2005
    ..Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia...
  14. doi request reprint Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator
    Junliang Hao
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Bioorg Med Chem Lett 23:1249-52. 2013
    ..Consistent with the hypothesis that blockade of mGlu5 receptors will produce analgesic effects in mammals, compound 24 produced a dose-dependent reduction in paw licking responses in the formalin model of persistent pain...
  15. ncbi request reprint Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats
    Rosa Maria A Simmons
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Mail Drop 0510, Indianapolis, IN 46285, USA
    Pharmacol Biochem Behav 73:419-27. 2002
    ..These results support the involvement of Group II mGlu2,3 receptors in persistent pain mechanisms and suggest the potential utility of selective Group II mGlu agonists for the treatment of persistent pain...
  16. ncbi request reprint Depression and pain
    Michael J Robinson
    Lilly USA, LLC, Indianapolis, IN 46285, USA
    Front Biosci (Landmark Ed) 14:5031-51. 2009
    ..To break this cycle, it is important to treat all symptoms of a patient. Therapeutic approaches that address symptoms of both depression and pain include psychotherapy, exercise, and pharmacotherapy...
  17. doi request reprint Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects
    Jill C Chappell
    From Eli Lilly and Company, Indianapolis, IN Institute of Clinical Chemistry and Laboratory Medicine Department of Medicine, University of Dresden, Dresden, Germany Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA MMS Holdings, Inc, Canton, MI Eli Lilly and Company, Windlesham, Surrey, UK Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL Detke Biopharma Consulting, LLC and Indiana University School of Medicine, Indianapolis, IN
    J Clin Psychopharmacol 34:9-16. 2014
    ....
  18. doi request reprint Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder
    Johannes Tauscher
    Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
    Eur Neuropsychopharmacol 20:80-7. 2010
    ..Thus, further evaluation of LY686017 for the treatment of SAD does not seem warranted...
  19. ncbi request reprint Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats
    Carrie K Jones
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Pharmacol Exp Ther 319:396-404. 2006
    ..The present studies provide further evidence that selective Glu(K5) kainate receptor subtype antagonists can reverse allodynia and hyperalgesia, particularly in persistent pain states...
  20. ncbi request reprint Corticotropin-releasing factor mRNA and substance P receptor binding in the paraventricular hypothalamic nucleus, central nucleus of the amygdala, and locus coeruleus of Sprague-Dawley rats following restraint-induced stress
    Bang H Hwang
    Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    J Mol Neurosci 25:239-50. 2005
    ..In concert with the literature indicating SP antagonist's antidepressive effects, up-regulated SP receptors in the CeA might contribute to the development of stress-related depression...
  21. ncbi request reprint AMPA receptor potentiation can prevent ethanol-induced intoxication
    Nicholas Jones
    Neuroimaging Research Group, Institute of Psychiatry, Kings College London, London, UK
    Neuropsychopharmacology 33:1713-23. 2008
    ....
  22. ncbi request reprint A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
    Pain 119:5-15. 2005
    ..In conclusion, both duloxetine 60 mg QD and duloxetine 60 mg BID were effective and safe in the treatment of fibromyalgia in female patients with or without major depressive disorder...
  23. ncbi request reprint Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials
    Lesley M Arnold
    Women s Health Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45219, USA
    J Womens Health (Larchmt) 16:1145-56. 2007
    ....
  24. ncbi request reprint A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder
    Lesley M Arnold
    University of Cincinnati College of Medicine, Cincinnati, Ohio 45219, USA
    Arthritis Rheum 50:2974-84. 2004
    ..To assess the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in subjects with primary fibromyalgia, with or without current major depressive disorder...